Clinical Trial Update: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. [Phase 2]

View source ↗

Summary

Phase 2 trial of inhaled TQC3721 in patients with moderate to severe chronic obstructive pulmonary disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• TQC3721

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED